Brain Natriuretic Peptide Levels in Constrictive Pericarditis and Restrictive Cardiomyopathy  by Babuin, Luciano et al.
permanent device implantation. We believe this system can be
readily implemented in such clinical scenarios.
*Paul C. Zei, MD, PhD
*Cardiac Arrhythmia Service
75 Francis Street
Brigham and Women’s Hospital
Boston, Massachusetts 02115
E-mail: pzei@partners.org
Robert E. Eckart, DO
Laurence M. Epstein, MD
doi:10.1016/j.jacc.2006.01.006
Please note: Dr. Zei is a research consultant for Biosense Webster Inc., and Dr.
Epstein is a consultant for Boston Scientific Inc., Guidant Inc., and Medtronic Corp.
REFERENCES
1. Lang R, David D, Klein HO, et al. The use of the balloon-tipped
floating catheter in temporary transvenous cardiac pacing. Pacing Clin
Electrophysiol 1981;4:491–6.
2. Trigano JA, Birkui PJ, Mugica J. Noninvasive transcutaneous cardiac
pacing: modern instrumentation and new perspectives. Pacing Clin
Electrophysiol 1992;15:1937–43.
3. Asano M, Mishima A, Ishii T, Takeuchi Y, Suzuki Y, Manabe T.
Surgical treatment for right ventricular perforation caused by trans-
venous pacing electrodes: a report of three cases. Surg Today 1996;26:
933–5.
4. Darouiche RO. Treatment of infections associated with surgical im-
plants. N Engl J Med 2004;350:1422–9.
5. Koplan BA, Stevenson WG, Epstein LM, Aranki SF, Maisel WH.
Development and validation of a simple risk score to predict the need
for permanent pacing after cardiac valve surgery. J Am Coll Cardiol
2003;41:795–801.
6. McAlister HF, Klementowicz PT, Andrews C, Fisher JD, Feld M,
Furman S. Lyme carditis: an important cause of reversible heart block.
Ann Intern Med 1989;110:339–45.
7. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002
guideline update for implantation of cardiac pacemakers and antiar-
rhythmia devices: summary article. J Cardiovasc Electrophysiol 2002;
13:1183–99.
8. Rastan AJ, Doll N, Walther T, Mohr FW. Pacemaker dependent
patients with device infection—a modified approach. Eur J Cardiotho-
rac Surg 2005;27:1116–8.
9. Pinto N, Jones TK, Dyamenahalli U, Shah MJ. Temporary transvenous
pacing with an active fixation bipolar lead in children: a preliminary
report. Pacing Clin Electrophysiol 2003;26:1519–22.
Brain Natriuretic Peptide Levels in Constrictive Pericarditis and Restrictive Cardiomyopathy
To the Editor: Constrictive pericarditis (CP) often is a challeng-
ing diagnosis despite sophisticated modalities (1–4). If a simple
test could alert physicians to the possibility of CP in patients with
evidence of heart failure, it would be valuable.
Recent data (5) suggest that brain natriuretic peptide (BNP),
released in response to cardiac stretch (6), is normal or only
minimally elevated in patients with CP and more elevated in
patients with restrictive cardiomyopathy (RCMP). However, there
are a variety of etiologies for CP. Many patients at our institution
present after either mantle chest radiation and/or open heart
surgical procedures (7). These patients may have additional myo-
cardial damage that could raise BNP even when concomitant CP
is present. To determine whether BNP levels in all patients with
CP are different from those with restriction, we studied patients
with well-documented CP and RCMP. We separated patients
with CP into those with idiopathic disease and with CP due to
secondary causes.
We reviewed 22 patients with surgically confirmed CP where
BNP was measured pre-operatively. Patients were divided into
those with idiopathic CP or secondary CP if there had been
previous cardiac surgery or chest radiation. We identified patients
with RCMP who had appropriately timed BNP values as a
comparison group. The diagnosis of RCMP was made according
to criteria by Hurrell et al. (4). These patients also had character-
istic echocardiographic findings. The diagnosis of CP was con-
firmed at surgery.
Two-dimensional echocardiographic examinations were per-
formed as previous reported (8); BNP measurements were per-
formed with the Biosite assay (La Jolla, California) close to the
time of the echocardiographic examinations and before surgical
pericardiectomy. The interval between echocardiogram and BNP
measurement was 1.3  7.4 days, and in all patients except 6, the
interval was 1 day.
Summary statistics are presented as frequencies (percentages)
for categorical variables, as mean  SD for the normal variables,
and as median and first and third quartile (Q1, Q3) for skewed
variables. The normal distribution of the variables was verified
performing the Shapiro-Wilk W test. Only BNP was very right
skewed. Log10-transformed values of BNP (Log10BNP) were
used in the analysis to obtain a normal distribution of the values.
Categorical variables were compared by Fisher exact test, contin-
uous normal variables by analysis of variance (followed by Tukey’s
HDS post-test). All tests were two-sided, and for all analyses p 
0.05 was considered statistically significant. Data were analyzed
with JMP Version 5 (SAS Institute Inc., Cary, North Carolina).
Twenty-two patients had surgically confirmed CP, 11 patients
had idiopathic CP, and 11 secondary CP (8 with previous cardiac
surgery and 3 with radiation therapy). They were compared to 11
patients with RCMP. Patient characteristics are reported in Table 1.
There were no significant differences among groups. Median BNP
was 80 (44 to 193) ng/l for idiopathic CP, 278 (118 to 526) ng/l
for secondary CP, and 499 (361 to 606) ng/l for RCMP. The
Log10-BNP was 1.9  0.3 ng/l for idiopathic CP, 2.4  0.3 ng/l
for secondary CP, and 2.7  0.2 ng/l for RCMP. There was a
statistically significant difference between the BNP values with
idiopathic CP and RCMP (p  0.05) and between patients with
idiopathic CP and those with secondary CP (p  0.05). There
were no significant differences in BNP between patients with
secondary CP and RCMP (Fig. 1).
All patients with BNP 150 ng/l had CP. Higher BNPs were
seen in patients with secondary CP and RCMP. The only
differentiating finding with RCMP was a BNP 650 ng/l, which
did not occur with CP.
Our data confirm and extend those recently published (5). Brain
natriuretic peptide levels were significantly lower in patients with
idiopathic CP than those with RCMP. However, BNP is not
significantly different in patients with CP secondary to previous
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cardiac surgery or radiation compared to those with RCMP. Thus,
BNP is a useful non-invasive marker to distinguish CP from
RCMP when CP is not due to a secondary cause. Relatively
normal BNP values in the setting of increased jugular venous
pressure should point to a diagnostic possibility of CP.
The findings of higher BNP values in secondary constriction are
important given in the modern era, previous cardiac surgery and
previous chest radiation therapy are more prevalent causes (7). In
these situations, higher values cannot be used to distinguish CP
from RCMP.
These data are consistent with the hypothesis proposed by Leya
et al. (5) that in patients with CP the myocardium may be
“intrinsically normal and myocardial stretch may be prevented by
the constraining pericardium.” This assumption is less valid in
patients with a history of additional cardiac disease. In these
patients, myocardial abnormalities may result in a higher release of
BNP than those with idiopathic CP. This distinction may have
been obscured in the prior study by the small number of patients
(six with CP and five with RCMP). Only three of the six patients
with the diagnosis of CP had a history of prior surgery, and those
patients with “history of radiation-induced cardiomyopathy” were
excluded.
The results of our study are important in clinical practice. The
differentiation of CP from RCMP can be more readily made in
cases of idiopathic CP versus pure RCMP. However, in those
cases of mixed myocardial and pericardial disease, the differential
diagnosis becomes more difficult.
Our study was a retrospective study with a modest-sized cohort
of non-consecutive patients. Hemodynamic data taken proximate
to the BNP values were not uniformly available.
In conclusion, BNP levels are significantly lower in patients
with idiopathic CP, compared to those with CP after surgery
and/or radiation and RCMP. Relatively normal BNP levels in
patients with right-sided heart failure should raise the suspicion of
CP. Higher levels cannot distinguish between CP and RCMP,
especially in patients with secondary CP.
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Table 1. Baseline Characteristics in the Patients With CP Idiopathic, CP Secondary,
and RCMP
CP Idiopathic
(n  11)
CP Secondary
(n  11)
RCMP
(n  11) p Value
Age (yrs), mean  SD 51.7  11.1 62.0  10.3 58.8  10.2 0.080
Women, n (%) 3 (27.3) 2 (18.2) 5 (45.4) 0.515
Pericardiectomy, n (%) 11 (100) 11 (100) 0 (0) 0.0001
BMI (kg/m2), mean  SD 30.5  5.3 27.6  4.2 29.1  6.0 0.451
HR (beats/min), mean  SD 85.9  13.2 76.3  16.9 76.0  15.7 0.242
Systolic blood pressure (mm Hg),
mean  SD
113.4  21.0 112.1  13.8 118.0  17.7 0.676
Diastolic blood pressure (mm Hg),
mean  SD
70.1  9.9 67.4  11.5 69.2  7.2 0.810
Ejection fraction (%), mean  SD 54.0  8.8 52.4  8.4 55.6  11.4 0.730
Cardiac index (l/min/m2),
mean  SD (n)
2.7  0.9 (9) 2.6  0.8 (11) 2.5  0.7 (10) 0.819
BNP (ng/l), median (Q1–Q3) 80 (44–193) 278 (118–526) 499 (361–606)
Log10-BNP (ng/l), mean  SD 1.9  0.3 2.4  0.3* 2.7  0.2* 0.0001
*p  0.05 vs. CP idiopathic.
BMI  body mass index; BNP  brain natriuretic peptide; CP  constrictive pericarditis; HR  heart rate; RCMP 
restrictive cardiomyopathy.
Figure 1. Log10 brain natriuretic peptide (BNP) in the three groups:
constrictive pericarditis (CP) idiopathic, CP secondary, and restrictive
cardiomyopathy (RCMP). *p  0.05 vs. CP idiopathic.
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Persistence of Neointimal Growth 12 Months After Intervention and Occurrence
of Delayed Restenosis in Patients With Left Main Coronary Artery Disease
Treated With Drug-Eluting Stents
To the Editor: Although long-term follow-up after drug-eluting
stent (DES) implantation shows a sustained clinical benefit in
several registries and randomized trials (1), little is known about
the pattern of neointimal growth beyond the first six to nine
months. In particular, when exactly neointima growth after DES
implantation begins to subside remains largely unknown.
The mechanism of action of DES on neointimal proliferation
seems to be partially explained by a delay in vascular response,
which has supported the concern that late restenosis (i.e., occurring
beyond six months) might occur in humans (2).
This would be of clinical relevance especially for patients
receiving DES implantation for the treatment of left main coro-
nary artery (LMCA) disease, in whom restenosis is considered a
major, and potentially fatal, complication after percutaneous in-
tervention.
Up to March 6, 2004, a total of 110 consecutive patients were
treated exclusively with one or more DES in the LMCA as part of
an elective or non-elective revascularization procedure at our
institution. Seventy-three patients received 6-month angiographic
follow-up, of whom 15 underwent paired angiographic measures at
12 months, which was not preceded by target vessel reintervention,
and constitute the patient population of the present report.
Quantitative angiographic analyses were performed with the use
of edge-detection techniques (CAAS II, Pie Medical, Maastricht,
the Netherlands). Binary restenosis was defined as stenosis of more
than 50% of the luminal diameter in the target lesion. Late loss was
defined as the minimal lumen diameter (MLD) immediately after
the index procedure minus the MLD at angiographic follow-up.
Continuous variables are shown as median and interquartile
range and were compared using Wilcoxon test or a general liner
mixed model followed by post-hoc analysis after log transforma-
tion for normalization. Probability was significant at a level of
0.05.
The characteristics of the study population (Table 1) did not
differ with respect to the patients receiving no or six-month
angiographic follow-up only.
The reason for repeating a second coronary angiogram included
risk-stratification before non-cardiac major surgery in three (Pa-
tients #1, #6, and #14), evidence of inducible ischemia at nonin-
vasive stress test in two (Patients #4 and #15), a staged procedure
for the treatment of the right coronary artery in one (Patient #13),
and the willingness to repeat a second coronary angiogram in the
remaining nine after counselling about the potential consequence
of in-stent restenosis at the time of the index procedure. No major
adverse cardiovascular event previously occurred in this cohort of
patients, and all except one were asymptomatic at the time of
repeated catheterization.
Quantitative coronary analysis on paired measurements in the
main treated branch (i.e., LMCA or LMCA and the proximal
tract of the left anterior descending artery) is shown in Table 1.
When all intervened coronary segments were cumulatively consid-
ered (n  20), including the stented proximal tract of the
circumflex artery in five patients receiving bifurcation stenting, the
MLD decreased from 2.78 (2.49 to 2.95) after the procedure to
2.44 mm (2.07 to 3.09) (p  0.37) and 2.25 (1.85 to 2.70) (p 
0.005 vs. post-procedure and p  0.054 vs. 6-month) at 6 and 12
months, respectively. The late loss (mm) increased from 0.29 (0.07
to 0.4) at 6 months to 0.63 (0.37 to 0.76) after 12 months (p 
0.001) (Fig. 1). Cumulatively, Patient #13, presenting with mild
intimal hyperplasia at 6 months, received a target vessel revascu-
larization at 12 months due to severe focal in-stent restenosis in the
mid-shaft of the LMCA (Fig. 1C), while a focal restenosis in the
ostium of the circumflex artery detected at 12-month follow-up in
Patient #2 was left untreated due to normal coronary reserve at
non-invasive nuclear stress imaging.
Previous serial angiographic analyses showed that intimal hyper-
plasia peaks after 12 to 16 weeks after intervention and that restenosis
rarely occurs beyond 3 months after bare metal stent implantation (3).
These observations justify current practice to perform angiographic
follow-up six to eight months after percutaneous coronary revascular-
ization, when the intimal growth has ceased and the net lumen gain
is likely to be maintained over time. Indeed, a partial regression of the
in-stent intimal hyperplasia at longer-term follow-up in patients
receiving bare metal stents has been reported (3).
When exactly neointima growth after DES implantation begins
to subside remains largely unknown, but based on experimental
findings, a late catch up phenomenon has been hypothesized (2). Of
some concern is the fact that similar argumentations have been
previously raised after intravascular brachytherapy, based on find-
ings on animals, which were subsequently confirmed in humans
(4). In the longest available angiographic follow-up after DES
implantation, neointimal growth has been shown to mildly non-
significantly progress beyond one year (1). Whether this would
result in delayed restenosis remained unclear.
In our small series of patients undergoing serial angiographic
monitoring, a significant increase of late loss between 6 and 12
months was noted, and, more importantly, one patient devel-
oped late in-stent restenosis of the LMCA, which necessitated
reintervention.
Our preliminary findings raise several unanswered questions.
This study was not pre-specified, as it was urged by the one-year
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